2-Amino-2-oxazolines as subtype selective α2 adrenoceptor agonists

Journal of Medicinal Chemistry

Volumn 43, Issue 9, 2000, Pages 1699-1704

  Wong, Wai C ^a,b   Sun, Wanying ^a,c   Cui, Weili ^a,d   Chen, Yuewen ^a,e   Forray, Carlos ^a   Vaysse, Pierre J J ^a   Branchek, Theresa A ^a   Gluchowski, Charles ^a,f  

^a H LUNDBECK A S   (Denmark)

^b BAYER CORPORATION   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d MicroSimulations   (United States)

^e James International Consulting Inc   (United States)

^f RiboGene Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 ETHYL 6 METHYLCYCLOHEXYLAMINO) 2 OXAZOLINE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLOHEXYLAMINO OXAZOLINE I; OXAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; MOLECULAR INTERACTION;

ADRENERGIC ALPHA-AGONISTS; ANTIHYPERTENSIVE AGENTS; CLONING, MOLECULAR; HUMANS; INDICATORS AND REAGENTS; MODELS, MOLECULAR; MONTE CARLO METHOD; OXAZOLES; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 0034103806     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9905256     Document Type: Article

References (27)

1. Hieble, J. P.; Bondinell, W. E.; Ruffolo, R. R., Jr. α-and β-Adrenoceptors: From the Gene to the Clinic. 1. Molecular Biology and Adrenoceptor Subclassification. J. Med. Chem. 1995, 38, 3415-3444.
2. Ruffolo, R. R., Jr.; Bondinell, W.; Hieble, J. P. α-and β-Adrenoceptors: From the Gene to the Clinic. 2. Structure-Activity Relationships and Therapeutic Applications. J. Med. Chem. 1985, 38, 3681-3716.
3. Pertovaara, A. Antinociception Induced by Alpha-2-Adrenoceptor Agonists with Special Emphasis on Medetomidine Studies. Prog. Neurobiol 1993, 40, 691-709.
4. 2-Adrenoceptor Agonists. Twist and Agent Polarity as Design Elements. Bioorg. Med. Chem. Lett. 1994, 4, 459-462.
5. 2Adrenergic Agonists. J. Med. Chem. 1997, 40, 18-23.
6. Lebrec, D. Current Status and Future Goals of The Pharmacologic Reduction of Portal Hypertension. Am. J. Surgery 1990, 160, 19-25.
7. (a) Lynch, K. R.; Harrison, J. K.; Pearson, W. R. Classification of Adrenergic Receptor Subtypes: Molecular Biologic Approaches. Neuroprotocols: A Companion to Methods in Neurosciences 1994, 4, 14-19.
8. 2-Adrenoceptor-Subtype Function. Trends Pharmacol. Sci. 1997, 18 (6), 211-219.
9. (c) Hein, L.; Altman, J. D.; Kobilka, B. K. Two Functionally Distinct Alpha2-Adrenergic Receptors Regulate Sympathetic Neurotransmission. Nature 1999, 402 (6758), 181-184.
10. (a) Wong, W. C.; Wang, D.; Forray, C.; Vaysse, P. J.-J.; Branchek, T. A.; Gluchowski, C. A Convenient Synthesis of 2-Amino-2-Oxazolines and Their Pharmacological Evaluation at Cloned Human a Adrenergic Receptors. Bioorg. Med. Chem. Lett. 1994, 4, 2317-2322.
11. th National Meeting of the American Chemical Society, San Francisco, April 13-17, 1997; American Chemical Society: Washington, DC, 1997; MEDI #23.
12. (a) Gluchowski, C. Method for Reducing or Maintaining Intraocular Pressure. U.S. Patent # 5,034,406, July 23, 1991.
13. th National Meeting of the American Chemical Society, San Diego, March 13-17, 1994; American Chemical Society: Washington, DC, 1994.
14. Jacob, F.; Werner, U.; Schumann, H. J. Zum Mechanismus der Antihypertensiven Wirkung des Oxazolin-Derivates BAY a6781. Arzneim.-Forsch. 1972, 22, 1124-1126.
15. th National Meeting of the American Chemical Society, New Orleans, March 24-28, 1996; American Chemical Society: Washington, DC, 1996; MEDI #23.
16. Hibert, M. F.; Trumpp-Kallmeyer, S.; Bruinvels, A.; Hoflack, J. Three-Dimensional Models of Neurotransmitter G-Binding Protein-Coupled Receptors. Mol. Pharmacol. 1991, 40, 8-15.
17. Goodford, P. J. A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules. J. Med. Chem. 1985, 28, 849-857.
18. Wilson, S. R.; Cui, W. Applications of Simulated Annealing to Peptides. Biopolymers 1990, 29, 225-235.
19. 2A-Adrenergic Receptors: Identification of Amino Acids Involved in Ligand Binding and Receptor Activation by Agonists. Mol. Pharmacol. 1991, 40, 168-179.
20. 2-Adrenergic Receptor. Biochemistry 1989, 28, 4125-4130.
21. Verbit, L.; Price, H. C. Optically Active Aromatic Chromophores. XI. Circular Dichroism Studies of Some 1-Substituted 2-Phenylcyclohexanes. J. Am. Chem. Soc. 1972, 94, 5143-5152.
22. Huynh, C.; Derguini-Boumechal, F.; Linstrumelle, G. Copper-Catalyzed Reactions of Grignard Reagents with Epoxides and Oxetanes. Tetrahedron Lett. 1979, 1503-1506.
23. 2B-Adren-ergic Receptor. Mol. Pharmacol. 1990, 38, 681-688.
24. 1Db Receptor. Mol. Pharmacol. 1992, 41, 1-7.
25. (b) Louis, W. J.; McNeil, J. J.; Anavekar, S. N.; Conway, E. L.; Workman, B.; Howell, L. G.; Drummer, O. H.; Jarrott, B. Comparison of Pharmacokinetics and Pharmacodynamics of Adrenoceptor Agonists and Antagonists as Antihypertensive Agents. J. Cardio-vasc. Pharmacol. 1987, 10 (Suppl. 12), S100-S103.
26. (a) Russell, P. B. The cis- and trans-2-Benzylcyclohexanols: The Reduction of 2-Benzylidene- and 2-Benzyl-cyclohexanones. J. Chem. Soc. 1954, 1771-1774.
27. (b) Fronza, G.; Fogliato, G.; Fuganti, C.; Lanati, S.; Rallo, R.; Servi, S. On the Mode of Baker's Yeast Reduction of Benzylidenecyclohexanone. Tetrahedron Lett. 1995, 36, 123-124.